The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hepatitis in Assisted Living Facilities

Back to News Homepage

Next

Vaccine Hopes Strengthen as Hep C Vulnerability Realized

Drug Companies Headed Toward Improving Hep C Therapy

September 8, 2011

Print this page

With the recent approval of the direct acting antivirals (DAA) Incivek and Victrelis, Hepatitis C treatment is improving. However, the next crop of DAAs has the potential to make Hepatitis C treatment even better.

Dramatic Changes in Hepatitis C Treatment Expected to Continue

Steve Worland 9/6/11

Earlier this year the FDA approved telaprevir (Incivek) from Vertex Pharmaceuticals and boceprevir (Victrelis) from Merck for the treatment of hepatitis C. Both agents are protease inhibitors and represent the first approvals of direct acting antivirals for hepatitis C. Direct acting antivirals are a broad class of agents that act to block the growth of viruses by directly disrupting essential viral functions. The benefit of these drugs for hepatitis C follows the dramatic success of this class over the last 15 years in HIV. Now the future advances of direct acting antiviral therapy for hepatitis C is expected to follow a central theme of their use in HIV: that combination of multiple antivirals in a single treatment regimen will provide greater benefit than use of any one antiviral drug alone.

Continue reading this entire article:
http://www.xconomy.com/san-diego/2011/09/06/dramatic-changes-in-hepatitis-c-treatment-expected-to-continue/

No Comments - be the first!
Share
Share

Previous

Hepatitis in Assisted Living Facilities

Back to News Homepage

Next

Vaccine Hopes Strengthen as Hep C Vulnerability Realized

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.